Skip to main content

Canaccord Genuity Sticks to Its Buy Rating for Adicet Bio (ACET)

Tipranks - Tipranks - Sat Aug 9, 2025

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Adicet Bio, with a price target of $8.00. The company’s shares closed yesterday at $0.69.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Newman is an analyst with an average return of -4.1% and a 34.88% success rate. Newman covers the Healthcare sector, focusing on stocks such as Delcath Systems, Allogene Therapeutics, and Regeneron.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adicet Bio with a $5.25 average price target, a 664.08% upside from current levels. In a report released on July 24, Wedbush also maintained a Buy rating on the stock with a $5.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $1.64 and a one-year low of $0.45. Currently, Adicet Bio has an average volume of 496.9K.

Read More on ACET:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).